All In Biotech

Drug Trial Radar · NCT03719443

First in Human Study to Assess Safety of VIS649 in Healthy Subjects

A Phase 1, Randomized, Placebo-Controlled, Single Ascending Dose First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of VIS649 Administered Intravenously in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: May 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

51

Actual

Start

Oct 9, 2018

Primary completion

Aug 10, 2019

Study completion Aug 10, 2019

Sponsor

Sponsor type
Industry
First posted
Oct 25, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a phase 1, randomized, placebo-controlled, double-blind, single ascending dose study of IV VIS649 in healthy subjects. VIS649 is a monoclonal immunoglobulin G2 (IgG2) antibody targeting the B-cell growth factor APRILL. The study will enroll up to 45 subjects and will be conducted in up to 5 sequential dosing cohorts at four different dose levels, enrolling 9 subjects per cohort. Subjects will be randomized to VIS649 or placebo in a ratio of 7:2 (7 active, 2 placebo). Safety, pharmacokinetic (PK) and pharmacodynamic (PD) data from the initial cohorts will be assessed.

Conditions

  • Immunoglobulin A Nephropathy
  • IgAN - IgA Nephropathy
  • IgA Nephropathy

Interventions

  • VIS649Biological

    Single IV dose of study product on Day 1 of study

  • PlaceboBiological

    Singe IV dose of placebo administered via IV on Day 1 of study

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Summary of Treatment Emergent Adverse EventsTime frame: Baseline to day 112

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • California Clinical Trials Medical Group

    Glendale, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.